A New Model for Funding Cost-Effectiveness Research
Patients before profits
Public Good Pharma (PGP) is revolutionizing healthcare by developing a pharmaceutical cost-containment platform, integrating with health plans to reduce specialty drug spend through conducting self-funding “Interventional Pharmacoeconomic” (IVPE) clinical trials as a service and data-driven optimization to develop low-cost alternatives to high-cost specialty drugs (e.g. repurposed generic drugs / biosimilars, nutraceuticals, diets and lifestyle interventions).
By combining rigorous IVPE trials subject to regulatory oversight with outcome-based contracts, we generate valuable clinical data to support reimbursement of the most cost-effective “best-in-class” therapies without financial or legal risk to payers. This model drives rapid, sustainable innovation, significantly reduces healthcare costs, and expands patient access to high-value, affordable care.
Reduce Financial Toxicity
Improve Patient Outcomes
Unlike traditional pharma pursuing the inefficient and unsustainable “blockbuster drug” model, we have flipped this model on its head by finding and clinically-validating low-cost alternatives to high-cost drugs. This means our interests are aligned with patients and health insurers because we earn revenue from conducting self-funding IVPE trials. Our eventual goal is to seek FDA approval for these low-cost therapies, in order to maximize health equity.
We work with “payers” including self-insured employers, pass-through PBMs, state health plans and integrated health systems looking for an innovative way to manage specialty drug spend.
